Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

S.E. Grimm^*, W. Witlox, R. Wolff, A. Chalker, M. Hiligsmann, B. Wijnen, C. Ahmadu, S. Ryder, N. Armstrong, S. Duffy, I. Syndikus, J. Kleijnen, M.A. Joore

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

1 Erratum / corrigendum / retractions

1 results

Filter

2022

Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Grimm, S. E., Witlox, W., Wolff, R., Chalker, A., Hiligsmann, M., Wijnen, B., Ahmadu, C., Ryder, S., Armstrong, N., Duffy, S., Syndikus, I., Kleijnen, J. & Joore, M. A., May 2022, In: Pharmacoeconomics. 40, 5, p. 575-575 1 p.
Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic

Open Access